156 related articles for article (PubMed ID: 12902985)
1. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions.
Sato N; Fukushima N; Maehara N; Matsubayashi H; Koopmann J; Su GH; Hruban RH; Goggins M
Oncogene; 2003 Aug; 22(32):5021-30. PubMed ID: 12902985
[TBL] [Abstract][Full Text] [Related]
2. Citric acid promotes SPARC release in pancreatic cancer cells and inhibits the progression of pancreatic tumors in mice on a high-fat diet.
Xiao G; Wei Y; Xie R; Tsang Y; Gu J; Shen D; Ding M; Yuan J; Xu D; Fei J
FEBS J; 2024 Apr; 291(8):1699-1718. PubMed ID: 38245817
[TBL] [Abstract][Full Text] [Related]
3. A holistic approach to dissecting SPARC family protein complexity reveals FSTL-1 as an inhibitor of pancreatic cancer cell growth.
Viloria K; Munasinghe A; Asher S; Bogyere R; Jones L; Hill NJ
Sci Rep; 2016 Nov; 6():37839. PubMed ID: 27886258
[TBL] [Abstract][Full Text] [Related]
4. Osteonectin (SPARC) prognostic value in prostate cancer.
Chekhun V; Borikun T; Zadvornyi T; Mushii O; Stakhovsky E; Vitruk Y; Lukianova N
Pathol Res Pract; 2024 Feb; 254():155053. PubMed ID: 38199134
[TBL] [Abstract][Full Text] [Related]
5. Osteonectin influences growth and invasion of pancreatic cancer cells.
Guweidhi A; Kleeff J; Adwan H; Giese NA; Wente MN; Giese T; Büchler MW; Berger MR; Friess H
Ann Surg; 2005 Aug; 242(2):224-34. PubMed ID: 16041213
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M
J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer.
Vincent A; Herman J; Schulick R; Hruban RH; Goggins M
Lancet; 2011 Aug; 378(9791):607-20. PubMed ID: 21620466
[TBL] [Abstract][Full Text] [Related]
8. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
9. Modulation of matrix remodeling by SPARC in neoplastic progression.
Chlenski A; Cohn SL
Semin Cell Dev Biol; 2010 Feb; 21(1):55-65. PubMed ID: 19958839
[TBL] [Abstract][Full Text] [Related]
10. HDAC10 inhibition represses melanoma cell growth and BRAF inhibitor resistance via upregulating SPARC expression.
Ling H; Li Y; Peng C; Yang S; Seto E
NAR Cancer; 2024 Jun; 6(2):zcae018. PubMed ID: 38650694
[TBL] [Abstract][Full Text] [Related]
11. Secreted Protein Acidic and Rich in Cysteine (
Arqueros C; Salazar J; Gallardo A; Andrés M; Tibau A; Lidia Bell O; Artigas A; Lasa A; Ramón Y Cajal T; Lerma E; Barnadas A
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137452
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment.
Tanaka HY; Nakazawa T; Enomoto A; Masamune A; Kano MR
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765684
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies.
Kuznetsova A; Popova O; Panchenkov D; Dyuzheva T; Ivanov A
Clin Exp Med; 2023 Jul; 23(3):619-643. PubMed ID: 36085429
[TBL] [Abstract][Full Text] [Related]
14. The role of SPARC (secreted protein acidic and rich in cysteine) in the pathogenesis of obesity, type 2 diabetes, and non-alcoholic fatty liver disease.
Atorrasagasti C; Onorato AM; Mazzolini G
J Physiol Biochem; 2023 Nov; 79(4):815-831. PubMed ID: 36018492
[TBL] [Abstract][Full Text] [Related]
15. Activity of acute pancreatitis is modified by secreted protein acidic and rich in cysteine ablation.
Ammer-Herrmenau C; Wolf L; Nasrin SS; Ramu I; Roggiolani R; Goetze RG; Buchholz SM; Sendler M; Ellenrieder V; Neesse A
United European Gastroenterol J; 2022 Jul; 10(6):544-555. PubMed ID: 35699570
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of SPARC Expression in Breast Cancer: A Meta-Analysis and Bioinformatics Analysis.
Shi S; Ma HY; Han XY; Sang YZ; Yang MY; Zhang ZG
Biomed Res Int; 2022; 2022():8600419. PubMed ID: 35211625
[TBL] [Abstract][Full Text] [Related]
17. Context Matters-Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer.
Sankarasubramanian S; Pfohl U; Regenbrecht CRA; Reinhard C; Wedeken L
Front Cell Dev Biol; 2021; 9():760705. PubMed ID: 34805167
[TBL] [Abstract][Full Text] [Related]
18. ECM Remodeling in Squamous Cell Carcinoma of the Aerodigestive Tract: Pathways for Cancer Dissemination and Emerging Biomarkers.
Fejza A; Camicia L; Poletto E; Carobolante G; Mongiat M; Andreuzzi E
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199373
[TBL] [Abstract][Full Text] [Related]
19. Fibronectin mediates activation of stromal fibroblasts by SPARC in endometrial cancer cells.
Yoshida S; Asanoma K; Yagi H; Onoyama I; Hori E; Matsumura Y; Okugawa K; Yahata H; Kato K
BMC Cancer; 2021 Feb; 21(1):156. PubMed ID: 33579227
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
